Introduction
============

Gynecological cancers are among the most common cancers in women and hence a major health problem worldwide (Maheshwari et al., 2016). Ovarian and cervical cancers are the most common gynecological cancers affecting women worldwide (Torre et al., 2017). Ovarian cancer is the second most common cancer and main cause of death with gynecological tumors worldwide (Qin et al., 2013; Zhu and Sun, 2017). Moreover, cervical cancer is the third most frequent neoplasm among women worldwide (Rocha et al., 2017). In 2017, a study showed that ovarian cancer (47%) followed by cervical cancer (29%) are the most common gynecological malignancy among Pakistan women (Manzoor et al., 2017). Despite continuous advances in cancer biology research, the etiology of ovarian and cervical cancer are not known exactly, partly because of the inconsistency of findings among epidemiological studies (Yu et al., 2013). A reappraisal of Genome-wide association studies (GWAS) and genetic association studies suggested a strong genetic component to susceptibility to ovarian and cervical cancers (Fearon et al., 2013).

Epidemiological studies had identified that Methylene tetrahydrofolate reductase (MTHFR) was a potential genetic marker of different malignancies (Yi et al., 2016; He and Shen, 2017). The human MTHFR gene is located on chromosome 1p36.3, consist of 11 exons and spans 2.2 kb of genomic DNA (Abedinzadeh et al., 2015; Azarpira et al., 2018). It is encodes the vital enzyme which plays a key role in the folate/homocysteine metabolic pathway and regulates the intracellular folate level for the synthesis and methylation of DNA (Azarpira et al., 2018; Kamali et al., 2018). In humans, the *MTHFR 677C\>T* (in exon 4) polymorphism has been heavily studied in different disease. The *MTHFR 677C\>T* is associated with reduced enzyme activity and arise an elevated plasma homocysteine level. Moreover, the *MTHFR 677C\>T* polymorphism leads to increased heat liability and reduced enzymatic capability for methylation of Homocysteine (Rozycka et al., 2014). The mutant homozygous genotype (TT) of *MTHFR 677C\>T* polymorphism was particularly common in northern China (20%), southern Italy (26%), and Mexico (32%) (Wilcken, 2003).

Over the past decades, a large number of epidemiological studies and meta-analyses have evaluated the association between the *MTHFR 677C\>T* polymorphism and susceptibility to ovarian and cervical cancer (Yi et al., 2016; He and Shen, 2017). However, the results were conflicting and inconclusive, presumably due to small sample size in each published study, various genetic backgrounds and possible selection bias (He and Shen, 2017). Subsequently, a few novel studies have recently been performed to estimate the associations of *MTHFR 677C\>T* polymorphism with risk of ovarian and cervical cancer and provide new evidences that were not included in the previous meta-analyses. Thus, this meta-analysis covering all potentially eligible studies was performed to get a more precise evaluation of the association between *MTHFR 677C\>T* polymorphism and risk of ovarian and cervical cancers.

Materials and Methods
=====================

*Literature Search Strategy*

A comprehensive searched in PubMed, Google scholar, Web of Science, EMBASE, Chinese Biomedical database, and China National Knowledge Infrastructure (CNKI) databases was performed to obtain the all relevant studies investigated association of *MTHFR 677C\>T* polymorphism with risk of ovarian and cervical cancers up to October 15, 2018. The following keywords and terms were used: (''Gynecological Cancer'' OR ''Ovarian Cancer'' OR ''Epithelial Ovarian Cancer'' OR ''Cervical Cancer'') AND (''Methylene tetrahydrofolate reductase'' OR ''MTHFR'' OR ''677C\>T'' OR ''rs1801133'') AND ("Polymorphism" OR ''SNP'' OR ''Mutation'' OR "Variant" OR "Variation"). Moreover, the references of the retrieved articles manually checked for other potential studies that possibly have been missed in the initial search.

*Inclusion Criteria and Data Extraction*

Studies were included in the current meta-analysis only if they met all of the following criteria: a) studies with case-control or cohort design; b) only published studies; c) evaluated the association of *MTHFR 677C\>T* polymorphism with ovarian cancer and cervical cancer; and d) the number of *MTHFR 677C\>T* polymorphism genotypes in the cases and healthy control was reported to estimates odds ratio (OR) and 95% confidence interval (CI). The exclusion criteria were: a) abstracts, case reports, reviews, previous meta-analyses, posters, letters to editor and commentaries; b) animal studies; c) case only studies; d) linkage or sibling studies; e) studies did not calculated *MTHFR* polymorphisms genotype frequencies or which the number of genotypes and alleles could not be ascertained; f) studies on other polymorphisms of *MTHFR* gene; and g) overlapping studies and studies duplicate or containing previously published data. Moreover, if studies had overlapping data, only the study with the largest population or more recently published data was finally selected.

*Data Extraction*

Two authors (H.A and A.H) independently assessed the articles for their eligibility for inclusion and the needed data were carefully extracted based on the inclusion criteria above using a standard form. Any disagreements were solved by discussion with a third author (E.S). The following data were extracted for each study: first author's name, publication year, country, ethnicity, source of control (hospital-based or population-based), genotyping methods, and the number of alleles and genotypes in the cases and controls, minor allele frequency (MAF) among controls, and P-value for Hardy-Weinberg equilibrium (HWE).
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###### 

Characteristics of Studies Included in the Meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author        Country (Ethnicity)       SOC   Genotyping\   Case/Control   Cases   Controls   MAFs   HWE                                                      
                                                      Technique                                                                                                       
  ------------------- ------------------------- ----- ------------- -------------- ------- ---------- ------ ------ ------ ------ ------ ----- ------- ------ ------- --------
  Ovarian Cancer                                                                   CC      CT         TT     C      T      CC     CT     TT    C       T              

  Wu 2007             China (Asian)             HB    NA            81/8           17      40         24     74     88     32     35     13    99      61     0.381   0.515

  Terry 2010          USA (Caucasian)           HB    TaqMan        1059/1125      427     492        140    1346   772    499    488    138   1486    764    0.340   0.270

  Terry 2010          USA (Caucasian)           HB    TaqMan        158/496        71      72         10     184    92     210    217    55    637     327    0.339   0.925

  Terry 2010          USA (Caucasian)           HB    TaqMan        364/412        164     167        33     495    233    193    168    51    554     270    0.328   0.130

  Webb 2011           Australia (Caucasian)     PB    MassARRAY     1638/1278      744     709        185    2197   1079   571    568    139   1710    846    0.331   0.898

  Prasad 2011         India (Asian)             HB    PCR-PFLP      80/125         72      3          5      147    13     116    8      1     240     10     0.040   0.062

  Pawlik 2011         Poland (Caucasian)        PB    PCR-PFLP      136/16         67      55         13     189    81     63     79     18    205     115    0.359   0.360

  Jakubowska 2012     Poland (Caucasian)        HB    PCR-PFLP      985/335        423     446        116    1292   678    1447   1481   422   4375    2325   0.347   0.156

  Zhang 2012          China (Asian)             HB    PCR-PFLP      215/218        102     94         19     298    132    115    92     11    322     114    0.261   0.170

  Gao 2012            China (Asian)             HB    PCR-PFLP      224/432        97      100        27     294    154    232    178    22    642     222    0.257   0.100

  Özkılıç 2016        Turkey (Caucasian)        HB    PCR-PFLP      50/54          18      28         4      258    36     19     30     5     68      40     0.370   0.160

  Total                                                             4990/773       2202    2206       450    6610   3106   3497   3344   875   10338   5094   0.330   0.077

  Cervical Cancer                                                                  CC      CT         TT     C      T      CC     CT     TT    C       T              

  Lambropoulos 2003   Greece (Caucasian)        HB    PCR-PFLP      21/91          11      8          2      30     12     42     37     12    121     61     0.335   0.403

  Sull 2004           Korea (Asian)             HB    SNapShot      246/454        73      115        58     261    231    153    221    80    527     381    0.420   0.989

  Kang 2005           Korea (Asian)             HB    PCR-PFLP      79/74          27      32         20     86     72     30     32     12    92      56     0.378   0.487

  Zoodsma 2005        Netherlands (Caucasian)   HB    TaqMan        636/592        357     230        49     944    328    273    262    57    808     376    0.318   0.608

  Ma 2006             China (Asian)             HB    PCR-PFLP      111/111        20      53         38     93     129    33     60     18    126     96     0.432   0.286

  Delgado 2006        Mexico (Mixed)            HB    PCR-PFLP      70/89          18      34         14     70     62     20     49     20    89      69     0.500   0.340

  Nandan 2008         India (Asian)             HB    PCR-PFLP      62/77          36      0          26     72     52     53     0      24    106     48     0.312   ≤0.001

  Shekari 2008        India (Asian)             HB    PCR-PFLP      200/2          125     68         7      318    82     170    28     2     368     32     0.080   0.489

  Kohaar 2010         India (Asian)             HB    SNapShot      164/231        113     47         4      273    55     161    65     5     387     75     0.162   0.598

  Yang 2010           China (Asian)             HB    PCR-PFLP      391/382        229     85         77     530    234    182    166    34    536     234    0.306   0.658

  Mostowska 2011      Poland (Caucasian)        HB    PCR-PFLP      124/168        56      59         9      171    77     69     81     18    219     117    0.348   0.420

  Prasad 2011         India (Asian)             PB    PCR-PFLP      62/125         57      5          0      119    5      116    8      1     240     10     0.040   0.062

  Tong 2011           Korea (Asian)             HB    TaqMan        146/427        53      65         28     171    121    152    198    77    502     342    0.412   0.373

  Keyserling 2011     Germany (Caucasian)       HB    LDR-PCR       386/328        164     188        34     516    256    165    136    27    466     190    0.290   0.890

  Hajiesmaeil 2016    Iran (Asian)              HB    PCR-PFLP      22/74          13      7          2      21     11     34     36     4     104     44     0.297   0.157

  Gong 2018           China (Asian)             HB    TaqMan        146/11         34      70         42     138    154    20     52     38    92      128    0.582   0.764

  Total                                                             2866/3533      1386    1066       410    3813   1881   1673   1431   429   4783    2259   0.324   ≤0.001
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation, SOC, Source Of Control; HB, Hospital Based; PB, Population Based; NA, Not applicable; PCR-RFLP, Polymerase Chain Reaction-Restriction Fragment Length Polymorphism; AS-PCR, Allele-Specific PCR; MAF, Minor Allele Frequency; HWE, Hardy-Weinberg Equilibrium.

###### 

Pooled Results for Association of *MTHFR 677C\>T* Polymorphism with Risk of Ovarian and Cervical Cancer

  Subgroup          Genetic Model   Type of Model   Heterogeneity   Odds Ratio   Publication Bias                                           
  ----------------- --------------- --------------- --------------- ------------ ------------------ ------------- -------- -------- ------- -------
  Ovarian Cancer                                                                                                                            
  Overall           T vs. C         Random          99.38           ≤0.001       0.894              0.421-1.896   -0.293   0.770    0.212   0.388
                    TT vs. CC       Random          68.02           0.001        1.178              0.894-1.551   1.165    0.244    0.275   0.290
                    TC vs. CC       Fixed           26.73           0.190        1.059              0.978-1.147   1.402    0.161    1.000   0.798
                    TT+TC vs. CC    Random          50.52           0.027        1.087              0.956-1.236   1.276    0.202    0.640   0.414
                    TT vs. TC+CC    Random          61.22           0.004        1.110              0.876-1.406   0.862    0.389    0.350   0.295
  Ethnicity                                                                                                                                 
  Caucasian         T vs. C         Random          99.59           ≤0.001       0.634              0.240-1.676   -0.919   0.358    0.071   0.737
                    TT vs. CC       Fixed           10.34           0.350        0.975              0.854-1.113   -0.377   0.706    0.763   0.106
                    TC vs. CC       Fixed           15.31           0.313        1.032              0.948-1.123   0.728    0.467    0.548   0.543
                    TT+TC vs. CC    Fixed           21.59           0.265        1.018              0.939-1.103   0.429    0.668    0.367   0.339
                    TT vs. TC+CC    Fixed           0.00            0.423        0.958              0.845-1.085   -0.675   0.500    1.000   0.127
  Asian             T vs. C         Fixed           9.75            0.344        1.493              1.259-1.772   4.595    ≤0.001   0.734   0.351
                    TT vs. CC       Fixed           0.00            0.578        2.818              1.857-4.277   4.869    ≤0.001   0.308   0.377
                    TC vs. CC       Fixed           11.47           0.335        1.300              1.023-1.651   2.147    0.032    0.734   0.880
                    TT+TC vs. CC    Fixed           3.27            0.376        1.483              1.183-1.859   3.415    0.001    1.000   0.547
                    TT vs. TC+CC    Fixed           0.00            0.608        2.329              1.575-3.445   4.233    ≤0.001   1.000   0.324
  Cervical Cancer                                                                                                                           
  Overall           T vs. C         Random          73.78           ≤0.001       1.132              0.956-1.341   1.434    0.151    0.620   0.232
                    TT vs. CC       Random          49.57           0.013        1.212              0.924-1.590   1.388    0.165    0.964   0.802
                    TC vs. CC       Random          77.11           ≤0.001       0.985              0.755-1.284   -0.113   0.910    0.843   0.438
                    TT+TC vs. CC    Random          79.60           ≤0.001       1.095              0.842-1.423   0.677    0.498    0.752   0.215
                    TT vs. TC+CC    Random          83.79           ≤0.001       1.410              0.913-2.176   1.551    0.121    0.620   0.867
  Ethnicity                                                                                                                                 
  Caucasian         T vs. C         Fixed           45.38           0.160        1.071              0.891-1.287   0.733    0.464    1.000   0.431
                    TT vs. CC       Fixed           8.40            0.336        0.996              0.637-1.559   -0.016   0.987    1.000   0.439
                    TC vs. CC       Fixed           27.78           0.250        1.197              0.930-1.540   1.393    0.164    1.000   0.413
                    TT+TC vs. CC    Fixed           44.89           0.163        1.162              0.912-1.480   1.214    0.225    1.000   0.406
                    TT vs. TC+CC    Fixed           0.00            0.573        0.913              0.594-1.403   -0.415   0.678    1.000   0.470
  Asian             T vs. C         Random          77.58           ≤0.001       1.173              0.958-1.438   1.542    0.123    0.427   0.119
                    TT vs. CC       Random          55.31           0.008        1.295              0.944-1.776   1.602    0.109    0.854   0.530
                    TC vs. CC       Random          79.26           ≤0.001       0.967              0.705-1.325   -0.211   0.833    0.945   0.264
                    TT+TC vs. CC    Random          82.20           ≤0.001       1.119              0.816-1.532   0.697    0.486    0.427   0.116
                    TT vs. TC+CC    Random          86.09           ≤0.001       1.594              0.961-2.642   1.806    0.071    0.582   0.924

*Statistical Analysis*

The strength of association between *MTHFR 677C\>T* polymorphism and ovarian and cervical cancers was assessed by using odds ratios (ORs) and 95% confidence intervals (CIs). The P-value of the pooled ORs was considered significant if less than 0.05, which was examined by Z-test. The pooled ORs were calculated under all five genetic models, i.e., allele (T vs. C), homozygote (TT vs. CC), heterozygote (TC vs. CC), dominant (TT+TC vs. CC), and recessive (TT vs. TC+CC), in which the ''C'' represents the major allele and the ''T'' represents the minor allele. The Cochran's Q-test was used to access the between-study heterogeneity. Moreover, the effects of heterogeneity was we quantified using I2 statistic (ranges from 0 to 100%), in which detected variations among studies due to heterogeneity rather than chance (I2= 0-25%, no heterogeneity; I2=25-50%, moderate heterogeneity; I2=50--75%, large heterogeneity; I2=75-100%, extreme heterogeneity) (Higgins 2003, Hippel 2015). A chi-square test was used to determine Hardy-Weinberg equilibrium (HWE) in controls, which p-value less than 0.05 was representative of statistical significance. Subgroup analyses were performed to explore possible sources of heterogeneity by ethnicity, source of controls, genotyping method and HWE status. Sensitivity analyses were performed by sequential removal of each study and by excluding those studies deviation from HWE to test the stability and reliability of the results. Visual inspection of asymmetry in funnel plots and Begg's rank correlation statistically were used to test whether publication bias existed or not, in which P\<0.05 was considered to be represented of statistically significant. All statistical analyses were performed using the Comprehensive Meta-Analysis (CMA) software version 2.0 (Biostat, USA). Two-sided P\<0.05 was considered statistically significant.

Results
=======

*Characteristics of Studies*

The flow diagram of study selection process was presented in [Figure 1](#F1){ref-type="fig"}. According to the initial searches, 123 studies were identified, which after removing duplicates and irrelevant studies, there were 69 studies left. Then, the titles and abstracts of the remaining articles were reviewed, 51 full-text articles were considered eligible. After carefully reviewing the remaining studies, 24 of them were excluded because did not reported sufficient data, were not case-control studies, overlapped by other studies, and not relevant to the *MTHFR 677C\>T* polymorphism ([Figure 1](#F1){ref-type="fig"}). Finally, 27 case-control studies with 7856 ovarian and cervical cancer cases and 11,263 controls were included. Among these studies, eleven case-control studies with 4990 cases 7730 controls were on ovarian cancer (Jakubowska et al., 2007; Wu et al., 2007; Terry et al., 2010; Prasad and Wilkhoo, 2011; Webb et al., 2011; Gao et al., 2012; Pawlik et al., 2012; Zhang et al., 2012; Özkılıç et al., 2016) and 16 case-control studies with 2,866 cases 3,533 controls were on cervical cancer (Lambropoulos et al., 2003; Sull et al., 2004; Zoodsma et al., 2005; Kang et al., 2005; Delgado-Enciso et al., 2006; Ma et al., 2006; Shekari et al., 2008; Nandan et al., 2008; Kohaar et al., 2010; Tong et al., 2011; von Keyserling et al., 2011; Yang et al., 2011; Mostowska et al., 2011; Prasad and Wilkhoo, 2011; Hajiesmaeil et al., 2016; Gong et al., 2018). The main characteristics of included studies were listed in [Table 1](#T1){ref-type="table"}. The studies were published from 2004 to 2018, and the sample sizes in cases groups ranged from 22 to 1,638. For ovarian cancer, seven studies were conducted in Caucasians and four in Asians. For cervical cancer, eleven studies were conducted in Asians, four in Caucasian, and one study in mixed population. All the 27 included studies were case-control studies, 24 of them were in a Hospital-Based (HB) and the remaining was Population-Based (PB) design. Five different genotyping methods were used including: PCR-PFLP, TaqMan, MassARRAY, SNapShot and LDR-PCR. The genotype distribution of the healthy subjects in all included studies was in agreement with the Hardy-Weinberg equilibrium (HWE), except one study for cervical cancer ([Table 1](#T1){ref-type="table"}).

*Quantitative Synthesis*

*Ovarian Cancer*

The results of meta-analysis for association between the *MTHFR 677C\>T* polymorphism and ovarian cancer were listed in [Table 2](#T2){ref-type="table"}. In overall, pooled data showed that the *MTHFR 677C\>T* polymorphism did no significantly associated with an increased risk of ovarian cancer under all five genetic models, i.e., allele (T vs. C: OR = 0.894, 95% CI 0.421-1.896, p = 0.770), homozygote (TT vs. CC: OR = 1.178, 95% CI 0.894-1.551, p = 0.244); heterozygote (TC vs. CC: OR = 1.059, 95% CI 0.978-1.147, p = 0.161, [Figure 2A](#F2){ref-type="fig"}), dominant (TT+TC vs. CC: OR = 1.087, 95% CI 0.956-1.236, p = 0.202), and recessive (TT vs. TC+CC: OR = 1.110, 95% CI 0.876-1.406, p = 0.389). When stratified by ethnicity, there was a significant association between the *MTHFR 677C\>T* polymorphism and an increased risk of ovarian cancer in Asians under all five genetic models, i.e., allele (T vs. C: OR = 1.132, 95% CI 1.259-1.772, p ≤0.001), homozygote (TT vs. CC: OR = 1.212, 95% CI 1.857-4.277, p ≤0.001); heterozygote (TC vs. CC: OR = 0.985, 95% CI 1.023-1.651, p = 0.032), dominant (TT+TC vs. CC: OR = 1.095, 95% CI 1.183-1.859, p = 0.001), and recessive (TT vs. TC+CC: OR = 1.410, 95% CI 1.575-3.445, p ≤0.001), but not in Caucasians ([Table 2](#T2){ref-type="table"}).

*Cervical Cancer*

[Table 2](#T2){ref-type="table"} also summarizes the results of association between the *MTHFR 677C\>T* polymorphism and cervical cancer. Pooled data failed to show a significant association between *MTHFR 677C\>T* polymorphism and risk of cervical cancer under all five genetic models, i.e., allele (T vs. C: OR = 1.132, 95% CI 0.956-1.341, p = 0.151), homozygote (TT vs. CC: OR = 1.212, 95% CI 0.924-1.590, p = 0.165); heterozygote (TC vs. CC: OR = 0.985, 95% CI 0.755-1.284, p = 0.910), dominant (TT+TC vs. CC: OR = 1.095, 95% CI 0.842-1.423, p = 0.498, [Figure 2B](#F2){ref-type="fig"}), and recessive (TT vs. TC+CC: OR = 1.410, 95% CI 0.913-2.176, p = 0.121). Similarly, stratified analysis by ethnicity did not show a significant association between the *MTHFR 677C\>T* polymorphism and cervical cancer under all five genetic models in Asians and Caucasians ([Table 2](#T2){ref-type="table"}).

*Between-Study Heterogeneity Test*

In the current meta-analysis, there was obvious between-study heterogeneity under four genetic models for ovarian cancer and all five genetic models for cervical cancer in overall population ([Table 2](#T2){ref-type="table"}). Therefore, we performed subgroup analyses by ethnicity to assess the potential source of between-study heterogeneity. In subgroup analysis, between-study heterogeneity was disappeared for ovarian cancer in the Caucasian and Asian population, as well as in the Caucasian subgroup for cervical cancer. The subgroup analysis results showed that ethnicity might be the major source of between-study heterogeneity for both ovarian and cervical cancer in the current meta-analysis.

*Sensitivity Analysis*

Moreover, sensitivity analysis was performed to assess the influence of each independent study on the pooled ORs by the sequential removal of each individual study form the analysis. However, the results of the sensitivity analysis for both ovarian cancer and cervical cancer did not materially changed by removing any of each individual study. Moreover, sensitivity analysis was carried out by excluding the HWE-violating study (Nandan et al., 2008) for cervical cancer. However, excluding the study did not significantly affect the pooled ORs for cervical cancer, indicating the robustness and reliability of this meta-analysis.

*Publication Bias*

Begg's and Egger's tests were used to examine the potential publication bias in assessment of the association of *MTHFR 677C\>T* polymorphism with ovarian and cervical cancer risk in all genetic models. No asymmetry was observed in the Begg's rank correlation among the studies on ovarian and cervical cancer. [Figure 3](#F3){ref-type="fig"} showed the shape of the Begg's funnel plots for association between *MTHFR 677C\>T* polymorphism and risk of cervical cancer in recessive model (TT vs. TC+CC). Moreover, the Egger's linear regression test did not show any statistical evidence of publication bias among the studies on ovarian and cervical cancer ([Table 2](#T2){ref-type="table"}).

Discussion
==========

MTHFR is an important enzyme which has an important role in the regulation of methionine and homocysteine levels in folate metabolism. The *MTHFR 677C\>T* polymorphism is one of the most studied functional polymorphism in cancer development, which could reduce the production of *MTHFR* and affect enzyme activity (Kamali et al., 2018). Thus, the current meta-analysis was performed to evaluate the association of *MTHFR 677C\>T* polymorphism with susceptibility to ovarian and cervical cancers in women. Finally, 27 case-control studies including eleven studies on ovarian cancer and 16 studies on cervical cancer were selected. Therefore, the current meta-analysis was the largest scale study so far on *MTHFR 677C\>T* polymorphism association with ovarian and cervical cancers. This meta-analysis pooled data revealed that the *MTHFR 677C\>T* polymorphism was not associated with an increased risk of ovarian and cervical cancers in overall population. The negative results in this pooled analysis agrees with the previous meta-analysis on cervical cancer (Yi et al., 2016). However, He and Shen (2017) in meta-analysis of eight studies found that the *MTHFR 677C\>T* polymorphism was associated with ovarian cancer risk. The main strength of this meta-analysis in comparison with the previous meta-analyses was the total number of cases and healthy controls selected. Therefore, this meta-analysis more power to detect the small effects of the polymorphism than previous studies. However, we recommend increasing the sample size in future studies in order to increase the power to detect small effects of the *MTHFR 677C\>T* polymorphism on risk of ovarian and cervical cancers.

When stratified analysis by ethnicity was performed the results showed that the *MTHFR 677C\>T* polymorphism was significantly associated with ovarian cancer in Asians, but not in Caucasians. Similarly, He and Shen (2017) showed that the *MTHFR 677C\>T* polymorphism is a risk factor for ovarian cancer and also breast cancer in Asians. It seems that due to the some genetic and environmental differences between Asian and Caucasian populations, the *MTHFR 677C\>T* polymorphism might play a different role in the development of ovarian cancer in the two populations. However, the subgroup analysis did not show a significant association between *MTHFR 677C\>T* polymorphism and cervical cancer by ethnicity. However, the previous meta-analysis revealed that *MTHFR 677C\>T* polymorphism was significantly associated with cervical cancer in Asians (Yi et al., 2016).

Between-study heterogeneity refers to the variation in study results between different studies, which could affects pooled results of a meta-analysis (Kamali et al., 2017) and a significant problem when interpreting of a meta-analysis (Forat-Yazdi et al., 2017; Jafari-Nedooshan et al., 2017). Several factors such as sample size, ethnicity, source of controls, genotyping methods, participants demographic and lifestyle might lead to the heterogeneity among studies (Mehdinejad et al., 2017; Yazdi et al., 2017). Thus, to explore the potential sources of heterogeneity among studies, we conducted subgroup analyses by ethnicity, cancer, source of control, HWE and genotyping methods. However, the subgroup analysis results showed that only ethnicity was the main source of heterogeneity in this meta-analysis.

To the best knowledge, this meta-analysis was the most comprehensive and convicting on the association of the *MTHFR 677C\>T* polymorphism with susceptibility to ovarian and cervical cancer. However, there were some limitations in our meta-analysis which must be described. First, we have only focused those published studies in English and Chinese in the current meta-analysis. Second, in the current meta-analysis the number of studies and the sample size in the studies by other ethnicities such as Africans, Latinos and mixed populations were small. Therefore, the lack of power due to the small number of studies leaves it an open field by ethnicity. Third, our meta-analysis was not adjusted by the potential confounders, such as age, gender and lifestyle, because not all of the studies reported adjusted ORs potential confounders. Finally, the potential effect of *MTHFR 677C\>T* polymorphism might be affected by gene-gene and gene-environment interactions. However, due to the lack of original data limited further evaluation of potential gene-gene and gene-environment interactions and also interactions of other polymorphisms of*MTHFR* gene.

In summary, this meta-analysis demonstrated that the *MTHFR 677C\>T* polymorphism was not associated with an increased risk to ovarian and cervical cancer in overall population. However, *MTHFR 677C\>T* polymorphism was significantly associated with ovarian cancer in Asians, but not in Caucasians. Moreover, considering the limitations of the study, large well-designed studies from different ethnicities should be conducted to provide a better understanding of the association of *MTHFR 677C\>T* polymorphism with risk of ovarian and cervical cancer.
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